137 
1 MS. PFUND : Okay. 
2 My name is Nancy Pfund. I am a Research 
3 Associate in the Division of Health Services Research 
4 at Stanford University School of Medicine. The intro- 
5 ductory comments to the revised NIH guidelines by 
6 Secretary Califano and Dr. Fredrickson, make specific 
1 mention of the need to examine and refine the mechanisms 
8 for implementing and enforcing regulatory requirements for 
0 recombinant DNA research. In my testimony I will address 
10 this issue as it relates to the local regulatory unit, 
H the institutional biosafety committee. 
12 First, I will comment on the importance of the 
13 IBC in shaping a representative and efficient regulatory 
14 policy. I will then discuss the results of some preliminary 
15 data we have obtained on a sample of 30 IBC's. Finally, 
^6 I will outline some plans for further research designed 
17 to fill gaps in current knowledge about the structure and 
18 function of IBC's. This research is part of a larger 
19 project, of which I am a member, entitled "Medical Progress 
20 and the Public Ethical Issues in Biomedical Innovation." 
21 This project is funded largely through the National 
22 Science Foundation's program in Ethics and Values in 
23 Science and Technology. 
24 The latest versions of the NIH guidelines give 
25 major regulatory responsibility and decision-making power 
[229] 
